The oral dose-effect relationship for fluvoxamine: A fixed-dose comparison against placebo in depressed outpatients

Annals of Clinical Psychiatry

Volumn 8, Issue 3, 1996, Pages 139-151

  Walczak, Donna D ^a,l   Apter, Jeffrey T ^b   Halikas, James A ^c   Borison, Richard L ^d   Carman, John S ^e   Post, Gary L ^f   Patrick, Roger ^f   Cohn, Jay B ^g   Cunningham, Lynn A ^h   Rittberg, Barry ⁱ   Preskorn, Sheldon H ^j   Kang, Jasbir S ^k   Wilcox, Charles S ^g  

^a Solvay Pharmaceuticals Inc   (Netherlands)

^b University Medical at Princeton   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e Carman Research   (United States)

^f Denver Drug Research Center   (United States)

^g Pharmacology Research Institute   (United States)

^h Vine Street Clinic ^*  (United States)

ⁱ REGIONS HOSPITAL   (United States)

^j University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^k Aliquippa Hospital   (United States)

^l AMGEN INC   (United States)

more..

Author keywords

Depression; Dose response; Efficacy; Fluvoxamine; Side effects

Indexed keywords

FLUVOXAMINE MALEATE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 10344221000     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.3109/10401239609147751     Document Type: Article

References (31)

1. Claassen V, Davies JE: Fluvoxamine, a specific 5-hydroxy-tryptamine uptake inhibitor. Br J Pharmacol 1977; 160:505-516
2. Claassen V: Pharmacological properties of fluvoxamine maleate. Report No. 56648/10/81. Duphar; 1981
3. Amin MM, Ananth JV, Coleman BS, Darcourt G, Farkas T, Goldstein BJ, Lapierre YD, Paykel ES, Wakelin JS: Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study. Clin Neuropharmacol 1984; 7580-581
4. Cassano GB, Conti L, Massimetti G, Mengali F, Waekelin JS, Levine J: Use of a standardized documentation system (BLIPS/BDP) in the conduct of a multicenter international trial comparing fluvoxamine, imipramine and placebo. Psychopharmacol Bull 1986; 22(1):52-58 (abstract)
5. Feighner JP, Boyer WF, Meredith CH, Hendrickson GG: A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989; 4:239-244
6. Itil TM, Shrivastava R, Mukherjee S, Coleman BS, Michael ST: A double-blind, placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 1983; 15:4335-4383
7. Lapierre YD, Browne M, Horn E, Oyewumi LK, Sarantidis D, Roberts N, Badoe K, Tessier P: Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry 1987; 48(2):65-68
8. Benfield P, Heel RC, Lewis SP: Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32(6):481-508
9. Schatzberg AF: Dosing strategies for antidepressant agents. J Clin Psychiatry 1991; 52(5):14-20
10. Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC: Paroxetine versus placebo: A double- blind comparison in depressed patients. J Clin Psychiatry 1992; 53:434-438
11. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, Dessain EC, Itil TM, Lautin A: Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51(12, Suppl B):28-33
12. Rabkin JG, Stewart JW, McGrath PJ, Markowitz JS, Harrison W, Quitkin F: Baseline characteristics of 10 day placebo washout responders in anti- depressant trials. Psychiatry Res 1987; 21:9-22
13. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
14. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
15. Neter J, Wasserman W, Kutner MH: Applied Linear Statistical Models. Boston: Richard D. Irwin, 1990:623-625
16. Snedecor GW, Cochran WG: Attribute data with more than one degree of freedom. In: Snedecor GW, Cochran WG, eds. Statistical Methods. Ames: Iowa State University Press; 1967:244
17. Heeren T, D'Agostino R: Robustness of the two independent samples t-test when applied to ordinal scaled data. Stat Med 1987; 6:79-90
18. Silverberg AR: The analysis of variance when the data are discrete. Presented at the Joint Statistical Meetings. Washington, DC: Am Stat Assoc and Biometric Soc; 1989
19. Murphy DL, Pickar D, Alterman IS: Methods for the quantitative assessment of depressive and manic behavior. In: Burdoch El, Sudelovsky A, Gershon S, eds. The Behavior of Psychiatric Patients. Quantitative Techniques for Evaluation. New York: Marcel Dekher, 1982:355-392
20. Carroll BJ, Fielding JM, Blashki TG: Depression rating scales: A critical review. Arch Gen Psychiatry 1973; 28:361-366
21. Cain JW: Poor response to fluoxetine: Underlying depression, serotonergic overstimulation, or a "therapeutic window"? J Clin Psychiatry 1992; 53(8):272-277
22. Lipinski JF, Mallya G, Zimmerman P, Pope HG: Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50(9):339-342
23. Fava M, Rosenbaum JF: Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry 1993; 52(3):108-111
24. Dasgupta K: Additional cases of suicidal ideation associated with fluoxetine. Am J Psychiatry 1990; 147:1570 (abstract)
25. King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L: Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991; 30(2):179-186
26. Masand P, Gupta S, Dewan M: Suicidal ideation related to fluoxetine treatment. N Engl J Med 1991; 324:420 (abstract)
27. Lipinski JF, Mallya G, Zimmerman P, Pope HG: Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 1989; 50(9)339-342
28. Rush AJ: Problems associated with the diagnosis of depression. J Clin Psychiatry 1990; 51(6) Suppl:15-22
29. Rosholm JJ, Hallas J, Gram LF: Outpatient utilization of antidepressants: A prescription database analysis. J Affect Disord 1993; 27:21-28
30. Fogel BS: Major depression versus organic mood disorder: A questionable distinction. J Clin Psychiatry 1990; 51(2):53-56
31. Center for Drug Evaluation FDA: Excerpts of the summary basis of approval for Sertraline (Zoloft), Document 99684. Rockville, MD: Freedom of Information Office, Center for Drug Evaluation and Research, FDA; 1992